A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

about

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q50079741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@en

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@nl

type

Item

label

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@en

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@nl

prefLabel

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@en

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@nl

P1476

A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.

@en

P2093

Christopher Edwards

http://www.w3.org/2001/XMLSchema#string

Madiha Ashraf

http://www.w3.org/2001/XMLSchema#string

Riccardo Polosa

http://www.w3.org/2001/XMLSchema#string

Salvatore Bellinvia

http://www.w3.org/2001/XMLSchema#string

P2860

The changing landscape of biosimilars in rheumatology

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Structure-immunogenicity relationships of therapeutic proteins.

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

P304

1133-1142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0068

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29067885

http://www.w3.org/2001/XMLSchema#string